High-Dose Antiangiogenic Therapy for Glioblastoma: Less May Be More.?

Targeting angiogenesis in glioblastoma rapidly reduces vascular permeability and contrast enhancement on MRI and prolongs progression-free survival. The long-term efficacy of bevacizumab and other anti-angiogenic agents is limited, however, because of the rapid development of resistance. Alternative dosing approaches may be one mechanism of prolonging therapeutic efficacy. Clin Cancer Res; 17(19); 6109-11. (C) 2011 AACR.